Search

Your search keyword '"Andrew P Schachat"' showing total 268 results

Search Constraints

Start Over You searched for: Author "Andrew P Schachat" Remove constraint Author: "Andrew P Schachat"
268 results on '"Andrew P Schachat"'

Search Results

1. Oral eplerenone for the management of chronic central serous chorioretinopathy

2. Patient-Reported Complications after Intravitreal Injection and Their Predictive Factors

Catalog

Books, media, physical & digital resources

3. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma

6. Detection of Choroidal Neovascular Membrane Beneath Pigment Epithelial Detachment Using SD-OCTA

8. Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti–Vascular Endothelial Growth Factor

9. 36-Month Evaluation of Intravitreous Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab

10. A Prospective Randomized Comparative Dosing Trial of Ranibizumab in Bevacizumab-Resistant Diabetic Macular Edema

11. The Prevalence of Adverse Ocular Hemorrhagic Events in Patients Utilizing Oral Anticoagulant and Antiplatelet Therapy in Routine Clinical Practice

12. Long-Term Outcomes of Anti-VEGF Therapy in Patients With Macular Edema Secondary to Retinal Vein Occlusion

13. Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice

14. Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy

18. The Use of Genetic Testing in the Management of Patients With Age-Related Macular Degeneration

19. Optical coherence tomography of outer retinal holes in senile retinoschisis and schisis-detachment

20. Ophthalmology Retina Is Now Indexed in MEDLINE/PubMed

21. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience

22. Ophthalmology Retina Enters Year 4

24. Impact of an Electronic Decision Support Tool on Hydroxychloroquine Screening

25. Beta-Thalassemia Minor Manifesting as Proliferative Retinopathy

26. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis

27. Glucocorticoids: Structure, Signaling and Molecular Mechanisms in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema

28. Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion

29. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]

30. Setting Priorities

32. A retrospective study of the influence of the vitreomacular interface on macular oedema secondary to retinal vein occlusion

33. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration

34. VOLUMETRIC SINGLE-LAYER INNER RETINAL ANALYSIS IN PATIENTS WITH HYDROXYCHLOROQUINE TOXICITY

35. Pre–Retinal Surgery Identification of Novel Anticoagulation and Antiplatelet Agents

36. SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN ACUTE RETINAL PIGMENT EPITHELIITIS

37. If There Is Loss to Follow Up, Poor Outcomes May Be More Common after Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Retinopathy

39. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice

40. Non-contiguous recurrence or secondary choroidal melanoma following plaque radiotherapy

41. Ranibizumab in the treatment of age-related macular degeneration

42. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice

43. Neovascular Age-Related Macular Degeneration

44. Neovascular Age-Related Macular Degeneration

45. Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma

46. Nonleaking Cystoid Macular Edema as a Presentation of Hydroxychloroquine Retinal Toxicity

47. International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma

48. Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice

49. Nine-Year Incidence of Age-Related Macular Degeneration in the Barbados Eye Studies

50. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: ROUNDTABLE